Therapeutic Plasma Exchange Market is expected to grow at an 5.5% CAGR during the forecast period for 2025-2034.
Plasma exchange is a biological procedure that removes large-molecular-weight substances such as harmful antibodies from the plasma. In this procedure, a large portion of plasma containing abnormal matter and toxins are removed from the components of WBCs, RBCs, and platelets and then replaced with replacement fluid, like fresh frozen plasma (FFP) i.e., donor plasma or albumin. It is performed to treat several chronic diseases as the first-line or as second line of treatment therapy in neurological and non-neurological conditions.
Therapeutic plasma exchange (TPE) can rapidly decrease plasma viscosity. Thus, it can improve patient outcomes in critically ill patients with COVID-19 by reducing plasma viscosity and thereby enhancing blood flow.
Global Therapeutic plasma exchange market is expected to offer the lucrative growth in the near future due to the rising prevalence of chronic diseases and ongoing research and clinical trials to determine the efficacy of plasma exchange over other treatments. Also, the outbreak of a new viral disease, COVID – 19, is also creating a massive demand for therapeutic plasma exchange and thereby drive the global market.
The Global Therapeutic plasma exchange market is segmented on the basis of product & technologies, end-users, and region. Based on the base of product and technology, the market is divided into the product (consumables & devices) and technology (centrifugation & membrane separation). On the basis of indication, the market is divided into neurological disorders, hematology disorders, renal disorders, and metabolic disorders. On the basis of end-users, the market is divided into blood collection centres & blood component providers, hospitals & transfusion centres, and other end users. Based on region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. North America accounted for the largest share of the market in 2019, followed by Europe and Asia Pacific. On the other hand, the Asia Pacific is projected to have the highest growth rate during the forecast period.
|
Report Attribute |
Specifications |
|
Growth Rate CAGR |
CAGR of 5.5% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Product & Technologies, By Indication, By End-Users |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; South Korea; South East Asia |
|
Competitive Landscape |
Terumo BCT, Inc., Fresenius SE & Co. KGaA, Haemonetics Corporation, Asahi Kasei Medical Co. Ltd., B. Braun Melsungen AG, Baxter International Inc., Cerus Corporation, Kaneka Corporation, Kawasumi Laboratories, Inc., Nikkiso Co., Ltd., Miltenyi Biotec, Medica S.p.A., Medicap Clinic GmbH, and Others |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Therapeutic Plasma Exchange Market Snapshot
Chapter 4. Global Therapeutic Plasma Exchange Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Penetration & Growth Prospect Mapping
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Products & Technology Advancement in Ambulatory Mammography
Chapter 5. Market Segmentation 1: Products & Technology Estimates & Trend Analysis
5.1. Products & Technology & Market Share, 2024 & 2034
5.2. Market Size (Value) & Forecasts and Trend Analyses, 2021 to 2034 for the following Products & Technology:
5.2.1. Product
Consumables
Devices
5.2.2. Technology
Centrifugation
Membrane Separation
Chapter 6. Market Segmentation 1: Indications & Trend Analysis
6.1. Indications & Market Share, 2024 & 2034
6.2. Market Size (Value)& Forecasts and Trend Analyses, 2021 to 2034 for the following Indications:
6.2.1. Neurological Disorders
Guillain–Barré syndrome
Chronic inflammatory demyelinating polyneuropathy
Myasthenia gravis
Multiple sclerosis
PANDASa
6.2.2. Hematology Disorders
Thrombotic thrombocytopenic purpura
Atypical haemolytic uraemic syndrome
Hyperviscosity syndromes
Severe/symptomatic cryoglobulinaemia
6.2.3. Renal Disorders
Goodpasture’s syndrome
Wegener’s glomerulonephritis
Antibody-mediated renal transplant rejection
6.2.4. Metabolic Disorders
Familial hypercholesterolaemia (homozygous)
6.2.5. Other Indications
Chapter 7. Market Segmentation 1: End-Users & Trend Analysis
7.1. End-Users & Market Share, 2024 & 2034
7.2. Market Size (Value)& Forecasts and Trend Analyses, 2021 to 2034 for the following End-Users
7.2.1. Blood Collection Centres & Blood Component Providers
7.2.2. Hospitals & Transfusion Centres
7.2.3. Other End Users
Chapter 8. Therapeutic Plasma Exchange Market Segmentation 3: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Therapeutic Plasma Exchange Market revenue (US$ Million) estimates and forecasts Products & Technology, 2021-2034
8.1.2. North America Therapeutic Plasma Exchange Market revenue (US$ Million) estimates and forecasts by Indications, 2021-2034
8.1.3. North America Therapeutic Plasma Exchange Market revenue (US$ Million) estimates and forecasts End-Users, 2021-2034
8.1.4. North America Therapeutic Plasma Exchange Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
8.1.4.1. U.S.
8.1.4.2. Canada
8.2. Europe
8.2.1. Europe Therapeutic Plasma Exchange Market revenue (US$ Million) Products & Technology, 2021-2034
8.2.2. Europe Therapeutic Plasma Exchange Market revenue (US$ Million) estimates and forecasts by Indications, 2021-2034
8.2.3. Europe Therapeutic Plasma Exchange Market revenue (US$ Million) estimates and forecasts End-Users, 2021-2034
8.2.4. Europe Therapeutic Plasma Exchange Market revenue (US$ Million) by country, 2021-2034
8.2.4.1. Germany
8.2.4.2. Poland
8.2.4.3. France
8.2.4.4. Italy
8.2.4.5. Spain
8.2.4.6. UK
8.2.4.7. Rest of Europe
8.3. Asia Pacific
8.3.1. Asia Pacific Therapeutic Plasma Exchange Market revenue (US$ Million) Products & Technology, 2021-2034
8.3.2. Asia Pacific Therapeutic Plasma Exchange Market revenue (US$ Million) estimates and forecasts by Indications, 2021-2034
8.3.3. Asia Pacific Therapeutic Plasma Exchange Market revenue (US$ Million) estimates and forecasts End-Users, 2021-2034
8.3.4. Asia Pacific Therapeutic Plasma Exchange Market revenue (US$ Million) by country, 2021-2034
8.3.4.1. China
8.3.4.2. India
8.3.4.3. Japan
8.3.4.4. Australia
8.3.4.5. Rest of Asia Pacific
8.4. Latin America
8.4.1. Latin America Therapeutic Plasma Exchange Market revenue (US$ Million) Products & Technology, 2021-2034
8.4.2. Latin America Therapeutic Plasma Exchange Market revenue (US$ Million) estimates and forecasts by Indications, 2021-2034
8.4.3. Latin America Therapeutic Plasma Exchange Market revenue (US$ Million) estimates and forecasts End-Users, 2021-2034
8.4.4. Latin America Therapeutic Plasma Exchange Market revenue (US$ Million) by country, 2021-2034
8.4.4.1. Brazil
8.4.4.2. Rest of Latin America
8.5. MEA
8.5.1. MEA Therapeutic Plasma Exchange Market revenue (US$ Million) estimates and forecasts Products & Technology, 2021-2034
8.5.2. MEA Therapeutic Plasma Exchange Market revenue (US$ Million) estimates and forecasts by Indications, 2021-2034
8.5.3. MEA Therapeutic Plasma Exchange Market revenue (US$ Million) estimates and forecasts End-Users, 2021-2034
8.5.4. MEA revenue Therapeutic Plasma Exchange Market revenue (US$ Million) by country, (US$ Million) 2021-2034
8.5.4.1. South Africa
8.5.4.2. Rest of MEA
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. TERUMO BCT, INC.
9.2.2. FRESENIUS SE & CO. KGAA
9.2.3. HAEMONETICS CORPORATION
9.2.4. BAXTER INTERNATIONAL INC.
9.2.5. ASAHI KASEI MEDICAL CO. LTD.
9.2.6. BRAUN MELSUNGEN AG
9.2.7. CERUS CORPORATION
9.2.8. KANEKA CORPORATION
9.2.9. KAWASUMI LABORATORIES, INC.
9.2.10. NIKKISO CO., LTD.
9.2.11. MILTENYI BIOTEC
9.2.12. Other Prominent Players
Global Therapeutic Plasma Exchange Market Revenue (US$ Mn), by Product & Technology,
Global Therapeutic Plasma Exchange Market Revenue (US$ Mn), By Indication,
Global Therapeutic Plasma Exchange Market Revenue (US$ Mn), By End Users,
Global Therapeutic Plasma Exchange Market Revenue (US$ Mn), By Region,
North America Therapeutic Plasma Exchange Market Revenue (US$ Mn), by Country,
Europe Therapeutic Plasma Exchange Market Revenue (US$ Mn), by Country,
Asia Pacific Therapeutic Plasma Exchange Market Revenue (US$ Mn), by Country,
Latin America Therapeutic Plasma Exchange Market Revenue (US$ Mn), by Country, 2019-2030
Middle East & Africa Therapeutic Plasma Exchange Market Revenue (US$ Mn), by Country, 2019-2030
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
